The inaugural virtual Prostate Cancer Drug Development Summit lands at a crucial time as the first and only dedicated conference for large pharma, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery, translation, and clinical development of safe and effective treatments for prostate cancer.

Here’s a sneak peek of crucial topics to be addressed:

• Amgen examining Bi-specific T-cell engager immune therapies for the treatment of prostate cancer ​​​​​​
• Novartis and Advanced Accelerator Applications revealing PSMA, re-envision survival
• ​​​​​​Noxopharm evaluating whether Veyonda is the answer to safe and effective prostate cancer treatment
• The National Cancer Institute and the National Institutes of Health teaching optimization potential role for immunotherapy in biochemically recurrent prostate cancer
• The University of Texas, MD Anderson Cancer Center demonstrating strategies for overcoming the immunosuppressive prostate tumor microenvironment and whether there is still a role for chemotherapy and chemotherapy combinations

To find out more and view the 2021 speaker line-up, download the full event guide.

Join 60+ thought-leaders converging at the first industry-led meeting to gain the latest scientific insights with renowned Urologists/Oncologists and those striving to advance safe and effective therapeutic breakthroughs to patients in need.

To know more about Prostate Cancer Drug Development Digital Summit please click here.